QD Information Services (QDIS)
QDIS was founded in 2003 by Edward Vawter, PhD. We offer a variety of services including consulting, informational searches, and training courses. For those interested, the name comes from the Library of Congress classification code for chemistry information; QD.
About Edward Vawter
Edward Vawter brings well over a decade of experience in research and development in the pharmaceutical industry with both large and small companies. He has a PhD in organic chemistry from Purdue University and has been involved in the synthesis of multi-step complex pharmaceuticals including polymer drug conjugates through all stages of development. He has managed the outsourcing of development and manufacturing for multi-million dollar projects on an international basis. Edward also has five years of experience with development of polymer based drug conjugates as well as extensive analytical development knowledge related to polymers. He has experience with experimental design and data analysis; not only statistical analysis but also exploratory data analysis and building of models to represent behavior of chemical systems. His business experience as well as his solid technical background can help your company succeed.
Past Publications
Chemical Publications
Patent Application Pub No.: US 20030054977 A1, Pub Date: Mar. 20, 2003. Manufacture of Polyglutamate-Therapeutic Agent Conjugates; Anil Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter.
Book chapter from Polymer Drugs in the Clinical Stage Hiroshi Maeda, et. al. (Editors) "Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [Xyotax®], a Biodegradable Polymeric Drug Conjugate: Characterization, Preclinical Pharmacology, and Preliminary Clinical Data" by Jack Singer, Brian Baker, Peter De Vries, Anil Kumar, Scott Shaffer, Ed Vawter, Mary Bolton, and Pamela Garzone.
Efficient Asymmetric Synthesis of the Vasopeptidase Inhibitor BMS-189921 Singh, J.; Kronenthal, D. R.; Schwinden, M.; Godfrey, J. D.; Fox, R.; Vawter, E. J.; Zhang, B.; Kissick, T. P.; Patel, B.; Mneimne, O.; Humora, M.; Papaioannou, C. G.; Szymanski, W.; Wong, M. K. Y.; Chen, C. K.; Heikes, J. E.; DiMarco, J. D.; Qiu, J.; Deshpande, R. P.; Gougoutas, J. Z.; Mueller, R. H.; Org. Lett., 2003, 5(17), 3155-3158.
Book chapter from Process Chemistry in the Pharmaceutical Industry Kumar G. Gadamasetti (Editor) "A Practical Synthesis of Ifetroban Sodium" by Richard M. Mueller.
Apparent endo-mode cyclic carbopalladation with inversion of alkene configuration via exo-mode cyclization-cyclopropanation rearrangement Zbyslaw Owczarczyk, Frederic Lamaty, Edward J. Vawter, Ei-ichi Negishi; J. Am. Chem. Soc. 1992, 114(25), 10091-10092.
Effects of Oragonmetals on the Palladium-Catalyzed Tandem Carbopalladation–Cross Coupling for Preparing Stereodefined Exocyclic Alkenes Negishi E.; Noda, Y.; Lamaty, F.; Vawter E. J.; Tetrahedron Lett. 1990, 31, 4393
Steroselective Cyclic Carbolithiation of Alkyne Derivatives. A Stereoselective Synthesis of Exocyclic Alkenes Guangzhong Wu, Fredrick E. Cedarbaum, and Ei-ichi Negishi; Tetrahedron Lett. 1990, 31, 493.
Regioselective 1,4-Addition to alpha,beta-Unsaturated Ketones with Grignard Reagents Mediated by (N,N,N',N'-tetramethylethylenediamine)zinc(II) chloride Richard A. Kjonaas, Edward J. Vawter; J. Org. Chem. 1986, 51(21), 3993-3996.
Work Experience
10/03 to present President, QD Information Services LLC
- Responsible for all areas of operation for a consulting and information services business
- Attract and develop relationships with various potential clients
- Developed business plan for operations of the company
- Provide reports and data for clients on various topics related to science, marketing, and competitive intelligence.
08/98 - 12/03 Senior Staff Chemist, Therapeutics, Inc.
- Responsible for planning the development work for poly-glutamate polymer-paclitaxel conjugate (CT-2103) for four years
- Participated and presented information for several due diligence potential partnerships
- Responsible for manufacturing campaigns under current Good Manufacturing Practice at various vendor sites
- Responsible for initial vendor audit and selection
- Extensive knowledge of the chemistry of Paclitaxel
- Responsible for chemistry manufacturing and controls CT-2103 cross functional group (analytical development, process development, formulation development, quality control, quality assurance, document control, Active Pharmaceutical Ingredient manufacturing, Finished Product manufacturing)
- Core team member for CT-2103 (poly-glutamic acid paclitaxel polymer conjugate) on cross functional team (regulatory, marketing, research, preclinical/toxicology, project management, clinical) representing manufacturing, and quality control
- Responsible for three years for multimillion dollar budgets directly related to manufacturing and development; indirectly responsible for tens of millions of budget dollars and came within 3% of budget
04/97 - 08/98 Senior Process Development Chemist, Synthetech
- Designed and refined synthetic schemes for the synthesis of specialty amino acids and peptide building blocks
- Optimized and improved existing synthetic sequences
- Executed synthetic schemes and clarified results both at bench scale as well as pilot plant scale
- Analyzed and interpreted information to decide the further course of projects
- Performed troubleshooting of operations in the pilot plant when problems occurred
- Pilot plant experience (22 L flasks and 50-500 gal reactors)
06/92 - 04/97 Research Scientist, Bristol-Myers Squibb
- Designed and refined synthetic schemes for the synthesis of key targets
- Optimized and improved existing synthetic sequences for utilization in a kilo-lab
- Executed synthetic schemes and clarified results
- Analyzed and interpreted information to decide the further course of projects
